Treatment, Medication & Supplement Directory

A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.

Directory explains “what it is.”Guides explain how owners can discuss, use, monitor, or prepare for a treatment option with veterinary guidance.

5 entriesShowing 1–5

Veterinarian reviewing a molecular target concept and an unbranded oral medicine with a dog caregiver

Named profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.

Palladia / Toceranib · Prescription Drug · Targeted Therapy · Palladia · Dogs · After Targeted Therapy · During Targeted Therapy

Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy

Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…

Named profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.

Laverdia / Verdinexor · Prescription Drug · Targeted Therapy · Laverdia · Dogs · After Targeted Therapy · During Targeted Therapy

Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma

Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…

Prescription Drug · Targeted Therapy · Dogs & Cats · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Published Study

Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework

Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.

Prescription Drug · Targeted Therapy · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy · Limited / Emerging Evidence

Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review

Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.

Named profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.

Prescription Drug · Targeted Therapy · Masivet · Dogs · After Targeted Therapy · Before Targeted Therapy · During Targeted Therapy

Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors